Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

This debate will contrast broad use of immunotherapy with molecular profiling-guided individualized approaches in frontline care for metastatic endometrial cancer. Evaluate clinical trial data supporting immunotherapy across patient populations alongside evidence for tailoring therapy based on molecular subtypes, reviewing practical considerations in applying these strategies in routine practice. Speakers will illuminate how evolving data are reshaping personalized care in endometrial cancer care. This discussion will review key molecular subtypes and biomarkers that inform treatment selection, including implications for immunotherapy, targeted agents, and combination strategies. Explore practical challenges in testing, interpretation, and implementation in routine practice for endometrial cancer therapy, and gain insight into how precision medicine approaches can optimize outcomes in this population.